Alzheimer's disease

BMJ (Online)

Volumn 338, Issue 7692, 2009, Pages 467-471

  Burns, Alistair ^a,b   Iliffe, Steve ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; DONEPEZIL; GALANTAMINE; MEMANTINE; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR;

AGING; AGITATION; ALZHEIMER DISEASE; AMNESIA; AROMATHERAPY; BEHAVIOR THERAPY; BRAIN EMBOLISM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DOWN SYNDROME; FAMILY HISTORY; GENETIC ASSOCIATION; HEAD INJURY; HEART ATRIUM FIBRILLATION; HERPES SIMPLEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MASSAGE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PHOTOTHERAPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SMOKING; UNSPECIFIED SIDE EFFECT; WANDERING BEHAVIOR; ANAMNESIS; DISEASE COURSE; EARLY DIAGNOSIS; GENETICS; KINESIOTHERAPY; METHODOLOGY; MUTATION; RESTLESSNESS; RISK FACTOR; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMNESIA; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEPRESSIVE DISORDER; DISEASE PROGRESSION; EARLY DIAGNOSIS; EXCITATORY AMINO ACID AGONISTS; EXERCISE THERAPY; HUMANS; MEDICAL HISTORY TAKING; MUTATION; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RISK FACTORS; TREATMENT OUTCOME;

EID: 61849157257     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b158     Document Type: Review

References (24)

1. Ferri CP, PrinceM, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
2. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. Br J Psychiatry 1990;157:72-94.
3. Feldman H, Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology 2005;65:S10-7.
4. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813-7.
5. Matthews FE, McKeith I, Bond J, Brayne C; MRC CFAS. Reaching the population with dementia drugs: what are the challenges? Int J Geriatr Psychiatry 2007;7:627-31.
6. Brayne C. The elephant in the room - healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 2007;8:233-9.
7. Nestor PJ,Scheltens P, Hodges JR. Advances in the earlydetection of Alzheimer's disease. Nat Rev Neurosci 2004;5:S34-41.
8. Chong MS, Sahadevan S. An evidence-based clinical approach to the diagnosis of dementia. Ann Acad Med Singapore 2003;32:740-8
9. Spaan PE, Raaijmakers JG, Jonker C. Alzheimers's disease versus normal ageing: a review of the efficiency of clinical and experimental memory measures. J Clin Exp Neuropsychol 2003;25:216-33.
10. Leroi I, Lyketsos C. Neuropsychiatric aspects ofdementia. In: Burns A, O'Brien J, Ames D, eds. Dementia. 3rd ed. London:Hodder Arnold, 2005:55-64.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
12. Dubois. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 2007;6:734-46.
13. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42:473-80.
14. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
15. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-72.
16. Burns A, Byrne J, Ballard C, Holmes C. Sensory stimulation in dementia: an effective option for managing behavioural problems. BMJ 2002;325:1312-3.
17. Burns A, O'Brien J. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-55.
18. Waldemar G, Phung KTT, Burns A, Georges J, Hansen FR, Iliffe S, et al. Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 2007;22:47-54.
19. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
20. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
21. Holmes. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214 -9
22. O'Brien J. Antipsychotics for people with dementia. BMJ 2008;337:a602.
23. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003;51:657-64.
24. Callahan C, Boustani M, Unverzagt F, Austrom M, Damush T, Perkins A, et al. Effectiveness of collaborative care for older adults with Alzheimer's disease in primary care: a randomized controlled trial. JAMA 2006;295:2148-57.